top of page
Dragonfly News
Dragonfly's novel cytokines and TriNKET® NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.
February 15, 2024
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications
Trodelvy and HER-2 TriNKET combinations will be in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). WALTHAM, Mass.,...
bottom of page